> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Tanzeum
- URL: https://www.fdaweb.com/review-period-set-for-tanzeum/
- Published: 2016-06-10T12:00:00.000Z
- Updated: 2026-09-14T21:09:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135909

*Federal Register* Notice: FDA has determined the regulatory review period for Human Genome Sciences, Inc.'s Tanzeum is 3,014 days for extending a patent which claims the human biological product. Tanzeum is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-06-10/pdf/2016-13797.pdf?ref=fdaweb.com)